Ligand Pharmaceuticals to Acquire XOMA Royalty for $740 Million

Ligand Pharmaceuticals has announced its acquisition of XOMA Royalty in an all-cash deal valued at nearly $740 million, or $39 per share. This strategic move aims to expand Ligand's portfolio.

27 Apr, 10:00 — 27 Apr, 13:10

Post Share

Why this matters

This acquisition is significant for the biotechnology and pharmaceutical sectors, as it involves a major transaction between two companies focused on drug development and royalty streams. It could impact future investment strategies and market valuations within the industry.

Key entitiesLigand Pharmaceuticals XOMA Royalty

The Story

What 3 sources agree on, dispute, and miss

What sources agree on

Ligand Pharmaceuticals is acquiring XOMA Royalty
The acquisition price is approximately $740 million

Key claims2 agreed · 1 unverified

✓

Ligand Pharmaceuticals is buying XOMA Royalty

agreed·Yahooseeking-alphawsj

✓

The acquisition price is $739 million

agreed·Yahoowsj

The acquisition price is $39 per share

unverified·seeking-alpha

Coverage gaps

The per-share acquisition price

Reportedseeking-alpha

MissingYahoowsj

The Story

Analyzing sources…

Source Diversity

Moderate (37/100)

3 sources25/33

Spectrum spread— 2/5 buckets covered8/33

Far L

Left1

Left (1)

Yahoo

Center

Right2

Right (2)

seeking-alphawsj

Far R

Geographic diversity— 1 region4/34

US3

ℹAll sources from US region

Sources

Showing 3 of 3 sources

wsjHigh104d ago

Exclusive | Ligand Pharmaceuticals Is Buying Xoma for Nearly $740 Million - WSJ

Exclusive | Ligand Pharmaceuticals Is Buying Xoma for Nearly $740 Million WSJ

Read full article →

YahooMostly Factual104d ago

Ligand Pharmaceuticals buying Xoma Royalty for $739 million

Read full article →

seeking-alphaMixed104d ago

Ligand to buy XOMA Royalty for $39/share

Read full article →

Coverage Timeline

First report: wsj · 27 Apr, 10:00|Full coverage: 3 · 3h|Window: 3h

Left-leaningCenterRight-leaning

wsj27 Apr, 10:00First to report

Exclusive | Ligand Pharmaceuticals Is Buying Xoma for Nearly $740 Million - WSJ

2h later

seeking-alpha27 Apr, 11:32

Ligand to buy XOMA Royalty for $39/share

2h later

Yahoo27 Apr, 13:10Latest update

Ligand Pharmaceuticals buying Xoma Royalty for $739 million

Story evolution

Initial Report2026-04-27T10:00:00.000Z

The Wall Street Journal first reported the exclusive news of Ligand's acquisition of XOMA for nearly $740 million.

Detailed Pricing2026-04-27T11:32:03.000Z

Seeking Alpha provided additional detail, specifying the acquisition price at $39 per share.

Wider Confirmation2026-04-27T13:10:39.000Z

Yahoo Finance confirmed the acquisition and the $739 million price point, aligning with earlier reports.

PERSPECTA

PERSPECTA

Ligand Pharmaceuticals to Acquire XOMA Royalty for $740 Million

Why this matters

The Story

What sources agree on

Key claims2 agreed · 1 unverified

Coverage gaps

The Story

Source Diversity

Source Diversity

Sources

Exclusive | Ligand Pharmaceuticals Is Buying Xoma for Nearly $740 Million - WSJ

Ligand Pharmaceuticals buying Xoma Royalty for $739 million

Ligand to buy XOMA Royalty for $39/share

Coverage Timeline

Exclusive | Ligand Pharmaceuticals Is Buying Xoma for Nearly $740 Million - WSJ

Ligand to buy XOMA Royalty for $39/share

Ligand Pharmaceuticals buying Xoma Royalty for $739 million

Story evolution

Related Stories

Seoul Shares Open Higher on Bargain Hunting Following Wall Street Advance

Rhine River Faces Historic Low Water Levels, Threatening Shipping

Oil Prices Climb

Shippers warn Rhine could be 'split in two' by low water

PERSPECTA

Why this matters

Story evolution

The Story

What sources agree on

Key claims2 agreed · 1 unverified

Coverage gaps

Coverage matrix